The clinical applications of this finding have been demonstrated in other tumor types such as NSCLC, where good concordance between ALK-rearranged CTCs and ALK-positive tumor biopsies has been demonstrated (Pailler et al. 2013). This evidence concerns the gene ALK and non-small cell lung carcinoma.